Semaglutide vs Tirzepatide:
What's the Difference?

Introduction

If you're exploring medical weight loss options, you've likely heard of semaglutide (sold as Ozempic® and Wegovy®) and tirzepatide (sold as Mounjaro® and Zepbound®). These are currently the two most widely discussed medications for weight management, but they work differently and may be better suited for different patients.

This article provides educational information only and does not replace an individualized medical evaluation.

How They Work: The Key Difference

Both medications target hormones that regulate appetite and blood sugar, but they do so in different ways:

Semaglutide (GLP-1 Receptor Agonist)

Semaglutide mimics a single hormone called GLP-1 (glucagon-like peptide-1). This hormone is naturally released after eating and helps regulate appetite, slow gastric emptying, and improve insulin response.

• Targets GLP-1 receptors only
• FDA-approved for weight loss (Wegovy®) and diabetes (Ozempic®)
• Longer track record in clinical use

Tirzepatide (GIP + GLP-1 Receptor Agonist)

Tirzepatide is a "dual agonist" that mimics two hormones: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism may provide additional metabolic benefits for some patients.

• Targets both GLP-1 and GIP receptors
• FDA-approved for weight loss (Zepbound®) and diabetes (Mounjaro®)
• Newer medication with emerging long-term data

Weight Loss Results: What the Studies Show

Clinical trials have shown that both medications can support significant weight loss when combined with lifestyle changes. However, head-to-head comparisons suggest tirzepatide may produce modestly greater average weight loss in some populations.

That said, individual results vary significantly based on factors like starting weight, metabolic health, adherence to treatment, and lifestyle factors. The "best" medication is the one that works safely for the individual patient.

Side Effects: What to Expect

Both medications share similar side effect profiles because they affect the same hormonal pathways. Common side effects include:

• Nausea (especially during dose titration)
• Vomiting
• Diarrhea or constipation
• Abdominal discomfort
• Decreased appetite

Most side effects are manageable and tend to improve as the body adjusts to the medication. Gradual dose titration—starting low and increasing slowly—helps minimize these effects.

Cost Considerations

Both brand-name medications are expensive without insurance coverage, often costing $1,000+ per month at retail prices. However, actual costs vary based on:

• Insurance coverage: Some plans cover these medications, especially for diabetes or with prior authorization
• Manufacturer programs: Savings cards and patient assistance programs may reduce costs
• Compounded options: Some patients access compounded versions at lower cost (with important considerations about quality and regulation)

Your clinician can help navigate options based on your insurance situation and budget.

Dosing and Administration

Both medications are administered as once-weekly subcutaneous injections. Patients self-administer using pre-filled injection pens at home.

Both follow a titration schedule, meaning the dose starts low and gradually increases over several weeks to months. This approach helps minimize side effects and allows your body to adjust.

Which One Is Right for You?

There's no universal "better" choice between semaglutide and tirzepatide. The right medication depends on:

• Your medical history and current health conditions
• Previous experience with weight loss medications
• Insurance coverage and cost considerations
• How your body responds to treatment
• Clinician recommendation based on your individual evaluation

A licensed clinician evaluates these factors during your consultation and recommends the most appropriate option—or may suggest that neither medication is the right fit for you.

Availability Through Telehealth

Both medications can be prescribed through telehealth services for eligible patients. At PeakHealth MT, we evaluate Montana residents via secure telemedicine consultations and prescribe medication when clinically appropriate.

All prescribing decisions are made following a comprehensive medical evaluation—not based on patient preference alone.

Key Takeaways

• Semaglutide targets GLP-1 receptors; tirzepatide targets both GLP-1 and GIP receptors
• Both can support significant weight loss when combined with lifestyle changes
• Side effects are similar and typically manageable with proper dose titration
• Cost varies significantly based on insurance, manufacturer programs, and pharmacy options
• The right choice depends on individual factors and clinical evaluation